[Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas]

MeSH terms

• Adolescent
• Antibodies, Monoclonal / administration & dosage
• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal / pharmacokinetics
• Antibodies, Monoclonal / therapeutic use*
• Antibodies, Monoclonal, Murine-Derived
• Antibody Specificity
• Antigens, CD20 / immunology
• Antigens, Neoplasm / immunology
• Child
• Child, Preschool
• Contraindications
• Female
• Humans
• Immunoconjugates / administration & dosage
• Immunoconjugates / adverse effects
• Immunoconjugates / pharmacokinetics
• Immunoconjugates / therapeutic use*
• Infant
• Lymphoma, B-Cell / immunology
• Lymphoma, B-Cell / radiotherapy
• Lymphoma, Non-Hodgkin / immunology
• Lymphoma, Non-Hodgkin / radiotherapy*
• Male
• Pregnancy
• Pregnancy Complications, Neoplastic / therapy
• Radiation Protection
• Radioimmunotherapy*
• Randomized Controlled Trials as Topic
• Rituximab
• Tissue Distribution
• Yttrium Radioisotopes / administration & dosage
• Yttrium Radioisotopes / adverse effects
• Yttrium Radioisotopes / pharmacokinetics
• Yttrium Radioisotopes / therapeutic use*